Table 3.
Univariate Analysis of Potential Factors Associated with PFS and OS
| Variables | PFS | OS | ||||
|---|---|---|---|---|---|---|
| Case | MST(m) | P | Case | MST(m) | P | |
| Age | ||||||
| <65 | 177 | 14.8(12.7–15.3) | 0.279 | 177 | 25.2(22.5–27.5) | 0.264 |
| ≥65 | 68 | 14.3(11.4–16.6) | 68 | 26.8(22.3–31.7) | ||
| Gender | ||||||
| Male | 107 | 11.6(10.7–13.3) | 0.057 | 107 | 28.2(25.9–30.1) | 0.010 |
| Female | 138 | 14.4(12.8–15.2) | 138 | 24.1(20.8–27.2) | ||
| Smoking status | ||||||
| No | 176 | 14.2(12.3–15.7) | 0.052 | 176 | 27.4(23.7–30.3) | 0.084 |
| Yes | 69 | 11.7(10.6–13.4) | 69 | 23.8(22.7–25.3) | ||
| ECOG PS | ||||||
| 0–1 | 204 | 14.4(12.4–15.6) | 0.007 | 204 | 28.3(25.7–30.3) | <0.001 |
| 2 | 41 | 10.7(9.3–12.7) | 41 | 18.6(16.3–21.7) | ||
| Brain metastasis | ||||||
| Yes | 26 | 11.1(9.4–12.6) | 0.043 | 26 | 22.8(19.1–26.9) | 0.038 |
| No | 219 | 14.4(12.4–15.6) | 219 | 26.2(23.7–28.3) | ||
| EGFR mutation | ||||||
| L858R | 101 | 11.9(10.1–13.9) | 0.590 | 101 | 24.1(17.7–30.3) | 0.829 |
| 19-DEL | 134 | 14.4(12.0–16.0) | 134 | 25.6(23.0–27.0) | ||
| Other | 10 | 12.0(NR) | 10 | 25.2(NR) | ||
| NLR | ||||||
| <3.36 | 135 | 14.8(13.6–16.4) | 0.128 | 135 | 27.8(26.1–29.9) | 0.004 |
| ≥3.36 | 110 | 11.7(10.8–13.2) | 110 | 21.7(19.4–24.6) | ||
| PLR | ||||||
| <167.01 | 123 | 14.3(11.7–16.3) | 0.268 | 123 | 26.8(23.5–30.5) | 0.281 |
| ≥167.01 | 122 | 11.8(10.6–13.4) | 122 | 23.9(21.4–26.6) | ||
| SIRI | ||||||
| <0.71 | 54 | 16.4(NR) | 0.002 | 54 | NR | 0.001 |
| ≥0.71 | 191 | 11.6(10.7–13.3) | 191 | 23.8(21.7–26.3) | ||
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; SIRI, systemic immune response index; NLR, neutrophil to lymphocyte ratio; PLR, platelet to lymphocyte ratio; OS, overall survival; PFS, progression-free survival; MST, mean survival time.